News
AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...
A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get the ...
በየሳምንቱ በባለሙያዎች የሚመከረው ያህል የአካል ብቃት እንቅስቃሴ ለማድረግ ብዙዎች ይቸገራሉ። የአካል ብቃት እንቅስቃሴ ለልብ ጤና ጠቃሚ ነው። የደም ...
At close: September 12 at 4:00:00 PM EDT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback